Beta Bionics announced that it successfully closed a Series D funding round, securing $100 million in new equity capital.
Concord, Massachusetts-based Beta Bionics develops its flagship iLet bionic pancreas. The autonomous insulin delivery system streamlines diabetes management and reduces the burden on patients and physicians. iLet received FDA clearance in May.
While Beta Bionics did not list an intended use of proceeds, the Series D funds could go toward commercialization efforts for iLet.
Get the full story at our sister site, Drug Delivery Business News.